JP2024516829A5 - - Google Patents

Info

Publication number
JP2024516829A5
JP2024516829A5 JP2023566519A JP2023566519A JP2024516829A5 JP 2024516829 A5 JP2024516829 A5 JP 2024516829A5 JP 2023566519 A JP2023566519 A JP 2023566519A JP 2023566519 A JP2023566519 A JP 2023566519A JP 2024516829 A5 JP2024516829 A5 JP 2024516829A5
Authority
JP
Japan
Prior art keywords
composition
compound
use according
eye
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023566519A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024516829A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2022/027045 external-priority patent/WO2022232586A1/en
Publication of JP2024516829A publication Critical patent/JP2024516829A/ja
Publication of JP2024516829A5 publication Critical patent/JP2024516829A5/ja
Pending legal-status Critical Current

Links

JP2023566519A 2021-04-30 2022-04-29 エンドセリンレセプターアンタゴニストを使用する眼疾患の処置 Pending JP2024516829A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163182750P 2021-04-30 2021-04-30
US63/182,750 2021-04-30
PCT/US2022/027045 WO2022232586A1 (en) 2021-04-30 2022-04-29 Treatment of ocular diseases using endothelin receptor antagonists

Publications (2)

Publication Number Publication Date
JP2024516829A JP2024516829A (ja) 2024-04-17
JP2024516829A5 true JP2024516829A5 (https=) 2025-05-12

Family

ID=83848733

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023566519A Pending JP2024516829A (ja) 2021-04-30 2022-04-29 エンドセリンレセプターアンタゴニストを使用する眼疾患の処置

Country Status (9)

Country Link
US (1) US20240058265A1 (https=)
EP (1) EP4329810A4 (https=)
JP (1) JP2024516829A (https=)
CN (1) CN117295520A (https=)
AU (1) AU2022264438A1 (https=)
CA (1) CA3218398A1 (https=)
IL (1) IL307794A (https=)
MX (1) MX2023012826A (https=)
WO (1) WO2022232586A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4329753A4 (en) * 2021-04-30 2025-02-26 Perfuse Therapeutics, Inc. PHARMACEUTICAL COMPOSITIONS AND INTRAVITREAL DRUG DELIVERY SYSTEMS FOR THE TREATMENT OF EYE DISEASES

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002049630A2 (en) * 2000-12-21 2002-06-27 Bristol-Myers Squibb Company Method for preventing or treating pain by administering an endothelin antagonist
US20070260203A1 (en) * 2006-05-04 2007-11-08 Allergan, Inc. Vasoactive agent intraocular implant
BRPI1013904A2 (pt) * 2009-04-30 2016-07-19 Univ Midwestern método e composição para tratar cetoacidose diabética
US20120087864A1 (en) * 2010-04-12 2012-04-12 R-Tech Ueno, Ltd. Method for diagnosing and/or evaluating retinal disease
CA2949954A1 (en) * 2014-05-23 2015-11-26 Ocular Technologies Sarl Topical formulations and uses thereof
WO2018185516A1 (en) * 2017-04-05 2018-10-11 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for treating cardiovascular toxicity induced by anti-cancer therapy
JP2020528082A (ja) * 2017-07-17 2020-09-17 ロイズマン，キース 加齢黄斑変性と他の眼疾患の治療用の細胞透過性ペプチドを使用する治療薬の局所送達
EP4050997A4 (en) * 2019-10-30 2022-11-30 Perfuse Therapeutics, Inc. TREATMENT OF EYE DISEASES USING ENDOTHELIN RECEPTOR ANTAGONISTS
CA3168810A1 (en) * 2020-02-06 2021-08-12 Perfuse Therapeutics, Inc. Compositions for treatment of ocular diseases
EP4329753A4 (en) * 2021-04-30 2025-02-26 Perfuse Therapeutics, Inc. PHARMACEUTICAL COMPOSITIONS AND INTRAVITREAL DRUG DELIVERY SYSTEMS FOR THE TREATMENT OF EYE DISEASES

Similar Documents

Publication Publication Date Title
Casson Medical therapy for glaucoma: A review
JP7470667B2 (ja) 眼の状態の治療のためのピロカルピン塩酸塩の使用
EP2262476B1 (en) Drug delivery to the anterior and posterior segments of the eye using eye drops.
WO2010125416A1 (en) Drug delivery to the anterior and posterior segments of the eye
JP6944958B2 (ja) 持続性浮腫を伴う滲出性加齢黄斑変性の処置のためのシロリムスの使用
JP2005523316A (ja) 眼科局所用のブリモニジンとチモロールとの組み合わせ
Boscia et al. Intravitreal triamcinolone acetonide in refractory pseudophakic cystoid macular edema: functional and anatomic results
JP6014033B2 (ja) 防腐剤無添加ビマトプロストおよびチモロール溶液
JP2022554277A5 (https=)
US20060111388A1 (en) Phenanthroline and derivatives thereof used to lower intraocular pressure in an affected eye
Ang et al. Prospective 12-month outcomes of combined iStent inject implantation and phacoemulsification in Asian eyes with normal tension glaucoma
Ha et al. Sovesudil (locally acting rho kinase inhibitor) for the treatment of normal‐tension glaucoma: the randomized phase II study
Jacklin Acute posterior multifocal placoid pigment epitheliopathy and thyroiditis
KR102266014B1 (ko) 안질환 예방 또는 치료용 점안 조성물
JP2024516829A5 (https=)
Fan et al. Comparison of the effect of reduced-fluence photodynamic therapy with intravitreal bevacizumab and standard-fluence alone for polypoidal choroidal vasculopathy
Lamichhane et al. Central retinal arterial occlusion (CRAO) after phacoemulsification-a rare complication
CN116898800A (zh) 无防腐剂的眼科药物乳剂及其应用
WO2002040028A1 (fr) Gouttes pour les yeux en gel antibacterien
TW201028176A (en) Compositions of topical ocular solutions to deliver effective concentrations of active agent to the posterior segment of the eye
JP2026505378A (ja) 視覚を改善するためのα２アドレナリン作動薬
Waheed et al. Intravitreal Triamcinolone For Refractory Diabetic Clinically Significant Macular Oedema
JP2024512028A (ja) Ｎ－オキソピリジン化合物の発生を抑制する眼疾患の予防または治療用点眼組成物
Gad Elkareem Intravitreal Ranibizumab Alone or Ranibizumab Combined with Thermal Laser Therapy for Diffuse Diabetic Macular Edema
Maruyama et al. Evaluation of the additive effect of bunazosin on latanoprost in primary open-angle glaucoma